Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy
- PMID: 2959265
- DOI: 10.1007/978-3-662-11289-2_39
Influence of phosphodiesterase inhibition on myocardial energetics in dilative cardiomyopathy
Abstract
The effects of inhibition of phosphodiesterase by enoximone on left ventricular haemodynamics and myocardial energetics were investigated in 10 patients with idiopathic dilative cardiomyopathy. After intravenous administration of enoximone, there was a significant reduction of left ventricular systolic pressure from 126 +/- 21 to 93 +/- 16 mm Hg, of left ventricular end-diastolic pressure from 16 +/- 8 to 5 +/- 3 mm Hg and of left ventricular end-diastolic volume from 287 +/- 54 to 215 +/- 69 ml. Left ventricular pressure-volume work decreased significantly from 12.1 +/- 3.6 to 7.6 +/- 2.8 mm Hg.l. Heart rate was 87 +/- 17 before and 103 +/- 18 min-1 after administration of enoximone (p less than 0.01). Left ventricular systolic stress-time integral, a major determinant of myocardial oxygen consumption, decreased by 49% from 91 +/- 32 to 46 +/- 15 10(3) dyn.s/cm2 (p less than 0.01). In contrast myocardial oxygen consumption per beat was reduced by only 18%, from 138 +/- 28 to 113 +/- 17 microliters O2/100 g (p less than 0.01). The economy of myocardial contraction as calculated by the ratio of systolic stress-time integral to myocardial oxygen consumption per beat was 675 +/- 192 before and 370 +/- 128 dyn.s.100 g/cm2.microliter O2 after administration of enoximone. In conclusion, the phosphodiesterase inhibitor enoximone exhibits vascular and myocardial effects. The myocardial effects result in decreased economy of myocardial contraction. The possible molecular mechanisms of these energetic changes are discussed.
Similar articles
-
Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone.Circulation. 1989 Jul;80(1):51-64. doi: 10.1161/01.cir.80.1.51. Circulation. 1989. PMID: 2525432
-
Influence of enoximone on myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside.J Cardiovasc Pharmacol. 1989;14 Suppl 1:S69-74. J Cardiovasc Pharmacol. 1989. PMID: 2480489
-
Cardiac energetics after intravenous enoximone in idiopathic dilated cardiomyopathy.Am J Cardiol. 1987 Aug 14;60(5):53C-56C. doi: 10.1016/0002-9149(87)90526-1. Am J Cardiol. 1987. PMID: 2956869 Clinical Trial.
-
Left ventricular geometry, myocardial function and energetics of the dilated left ventricle. Influence of vasodilators and positive inotropic substances.Herz. 1991 Sep;16 Spec No 1:298-303. Herz. 1991. PMID: 1820296 Review.
-
[Role of the enoximone-dobutamine combination in the treatment of congestive cardiac insufficiency].Arch Mal Coeur Vaiss. 1990 Sep;83 Spec No 3:33-7. Arch Mal Coeur Vaiss. 1990. PMID: 2147832 Review. French.
Cited by
-
Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.Klin Wochenschr. 1989 Jun 15;67(12):605-15. doi: 10.1007/BF01718141. Klin Wochenschr. 1989. PMID: 2671473 Review.
-
Enoximone. A review of its pharmacological properties and therapeutic potential.Drugs. 1991 Dec;42(6):997-1017. doi: 10.2165/00003495-199142060-00008. Drugs. 1991. PMID: 1724645 Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous